483
FujiFilm Diosynth Biotechnologies U.S.A., Inc.FDA 483 - FujiFilm Diosynth Biotechnologies U.S.A., Inc. - March 01, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Fujifilm Diosynth Biotechnologies in Morrisville, NC, from February 25 to March 1, 2019, revealed two significant observations. The firm was cited for an inadequately validated bioburden testing method for PPQ batches and for inadequate investigation of deviations, including issues with TOC swab failures and exhaust air filter integrity testing.
Open in Dashboard
ID · c726ae27-0006-43fa-8261-f05e9c6173fb